PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY RR Barreto; K Patel; C Coombs; N Shah; T Eyre; W Wierda; P Ghia; M Davids; W Jurczak; A Mato;

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY JR Brown; JA Woyach; K Patel; TA Eyre; Cy Cheah; P Ghia; W Jurczak; P Abada; WG Wierda; GFPN Presenter;

IMPACTO DA ASSINATURA GÊNICA ASSOCIADA AO PH-LIKE NOS DESFECHOS CLÍNICOS EM PACIENTES ADULTOS COM LLA-B EM CENÁRIOS DE RECURSOS LIMITADOS K Lima; CAO Rojas; FL Nogueira; WF Silva; RCC Medeiros; L Nardinelli; AM Leal; EDRP Velloso; I Bendit; A Alencar; CG Mullighan; JA Machado-Neto; EM Rego;